Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...

bringing basal insulin product Lantus (insulin glargine) into line with the cap mandated on insulin for seniors funded by Medicare in the Inflation Reduction Act. Sanofi will also slash the list ...

One group received two oral drugs (metformin plus the sulfonylurea glimepiride [Amaryl]) plus morning doses of glargine insulin (Lantus); the other group received twice-daily premixed insulin (70% ...